Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian s
10 hours ago
- #denosumab
- #breast cancer
- #bone metastases
- Denosumab may improve real-world progression-free survival (rwPFS) in BRCA1/2-mutated HR+/HER2- breast cancer patients with bone metastases receiving CDK4/6 inhibitors.
- The study found that among BRCA1/2-mutated patients, denosumab use was associated with a median rwPFS of 35 months vs. 13 months without denosumab.
- For BRCA1/2-wild-type/unknown patients, denosumab use did not significantly affect rwPFS.
- Multivariable analysis confirmed the rwPFS benefit of denosumab in BRCA1/2-mutated patients, with an adjusted hazard ratio of 0.45.
- The research suggests RANKL inhibition by denosumab could disrupt tumor-bone microenvironment crosstalk, especially in BRCA-mutated tumors.